STLN STARLING ONCOLOGY
Health Care · Russell 2000
Next earnings: not announced yet
What 6 analyst firms say about STARLING ONCOLOGY: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
5 rated views · 6 analyst/firm records · 6 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Price below 5 USD
- Russell 2000 · Safest consensus · 6MNot scored · Price below 5 USD
Recent analyst activity · last 90 days
Our tracked history has 1 report on STLN from 1 analyst firm in the last 90 days (6 firms in the past year).
Comparing each firm's latest target with its previous one: 1 raised its price target.
No firm's latest available rating differs from its previous one.
Latest observed target change: Needham raised its target from $7.00 (set 17 Jun 2026) to $9.00 on 14 Oct 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| B Riley Securities | Yuan Zhi | Buy | 6 Aug 2026 | 11.00 USD |
| BTIG | David Larsen | Buy | 9 Jul 2026 | 9.00 USD |
| Lake Street Capital Markets | Benjamin Haynor | Buy | 6 Jul 2026 | 10.00 USD |
| Needham | Matthew Shea | Buy | 14 Oct 2026 | 9.00 USD |
| Weiss Ratings | Unnamed analyst | — | 6 Aug 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 22 May 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 06:12 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.